Tebit D, Nickel G, Gibson R, Rodriguez M, Hathaway N, Bain K
EBioMedicine. 2024; 100:104965.
PMID: 38215691
PMC: 10827413.
DOI: 10.1016/j.ebiom.2023.104965.
Alzubaidee Sr M, Dwarampudi R, Mathew S, Bichenapally S, Khachatryan V, Muazzam A
Cureus. 2022; 14(9):e28960.
PMID: 36237744
PMC: 9547769.
DOI: 10.7759/cureus.28960.
Das D, Jena A, Banerjee A, Radhakrishnan A, Duttaroy A, Pathak S
Med Hypotheses. 2022; 166:110926.
PMID: 35935095
PMC: 9347142.
DOI: 10.1016/j.mehy.2022.110926.
Lomartire S, Goncalves A
Mar Drugs. 2022; 20(6).
PMID: 35736188
PMC: 9228758.
DOI: 10.3390/md20060385.
Bandarra S, Miyagi E, Ribeiro A, Goncalves J, Strebel K, Barahona I
J Virol. 2021; 95(23):e0117021.
PMID: 34523960
PMC: 8577350.
DOI: 10.1128/JVI.01170-21.
HIV-2 Drug Resistance Genotyping from Dried Blood Spots.
Raugi D, Nixon R, Leong S, Faye K, Diatta J, Sall F
J Clin Microbiol. 2020; 59(1).
PMID: 33055182
PMC: 7771475.
DOI: 10.1128/JCM.02303-20.
First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L
Clin Infect Dis. 2018; 67(8):1161-1167.
PMID: 29590335
PMC: 6160602.
DOI: 10.1093/cid/ciy245.
Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.
Saleh S, Vranckx L, Gijsbers R, Christ F, Debyser Z
J Virus Erad. 2017; 3(1):7-14.
PMID: 28275453
PMC: 5337426.
Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa.
Tchounga B, Honge B, Eholie S, Coffie P, Jespersen S, Wejse C
AIDS. 2016; 30(17):2707-2714.
PMID: 27536979
PMC: 5841585.
DOI: 10.1097/QAD.0000000000001232.
Mortality and survival patterns of people living with HIV-2.
Tchounga B, Ekouevi D, Balestre E, Dabis F
Curr Opin HIV AIDS. 2016; 11(5):537-544.
PMID: 27254747
PMC: 5055442.
DOI: 10.1097/COH.0000000000000299.
Engineering broadly neutralizing antibodies for HIV prevention and therapy.
Hua C, Ackerman M
Adv Drug Deliv Rev. 2016; 103:157-173.
PMID: 26827912
PMC: 4935580.
DOI: 10.1016/j.addr.2016.01.013.
Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
Raugi D, Smith R, Gottlieb G
J Virol. 2015; 90(2):1062-9.
PMID: 26559830
PMC: 4702657.
DOI: 10.1128/JVI.01772-15.
Rapid evolution of the env gene leader sequence in cats naturally infected with feline immunodeficiency virus.
Beczkowski P, Hughes J, Biek R, Litster A, Willett B, Hosie M
J Gen Virol. 2014; 96(Pt 4):893-903.
PMID: 25535323
PMC: 4361796.
DOI: 10.1099/vir.0.000035.
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Melard A, Collin G
J Clin Microbiol. 2014; 52(8):3017-22.
PMID: 24920771
PMC: 4136173.
DOI: 10.1128/JCM.00724-14.
HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts.
Raugi D, Gottlieb G, Sow P, Toure M, Sall F, Gaye A
AIDS. 2013; 27(15):2441-50.
PMID: 23665777
PMC: 4043222.
DOI: 10.1097/QAD.0b013e328362e856.
Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.
Raugi D, Smith R, Ba S, Toure M, Traore F, Sall F
Antimicrob Agents Chemother. 2013; 57(6):2751-60.
PMID: 23571535
PMC: 3716120.
DOI: 10.1128/AAC.00405-13.
Clinical predictors cannot replace biological predictors in HIV-2 infection in a community setting in West Africa.
Gourlay A, van Tienen C, Dave S, Vincent T, Rowland-Jones S, Glynn J
Int J Infect Dis. 2012; 16(5):e337-43.
PMID: 22387142
PMC: 3324712.
DOI: 10.1016/j.ijid.2012.01.001.
Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection.
Khalid M, Yu H, Sauter D, Usmani S, Schmokel J, Feldman J
J Virol. 2012; 86(9):4906-20.
PMID: 22345473
PMC: 3347365.
DOI: 10.1128/JVI.06856-11.
Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.
Peterson K, Jallow S, Rowland-Jones S, I de Silva T
AIDS Res Treat. 2011; 2011:463704.
PMID: 21490779
PMC: 3065912.
DOI: 10.1155/2011/463704.
Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai.
Chiara M, Rony Z, Homa M, Bhanumati V, Ladomirska J, Manzi M
Indian J Med Res. 2011; 132:683-9.
PMID: 21245615
PMC: 3102455.